Navigation Links
CrystalGenomics Initiates CG100649 Phase 2b Study in Patients with Osteoarthritis
Date:5/31/2011

SEOUL, South Korea, May 31, 2011 /PRNewswire/ -- CrystalGenomics, Inc. (Seoul, Korea) and CG Pharmaceuticals, Inc. (Emeryville, California), a biopharmaceutical company with 3 clinical stage candidates, has announced that the first patient has been enrolled for a Phase 2b clinical study of CG100649, CrystalGenomics' clinical stage novel NSAID candidate, in patients with knee or hip osteoarthritis (OA).

CG100649 is a first-in-class NSAID drug candidate that is a dual inhibitor of COX-2 and carbonic anhydrase (CA). CG100649's interaction with carbonic anhydrase in red blood cells provides it with a novel "tissue-specific" transport mechanism that is designed to deliver sustained levels of drug to inflamed tissues, while maintaining low systemic exposure. Its unique dual COX-2 and CA binding properties are designed to provide potentially superior safety to cardiovascular, renal, and gastrointestinal tissues compared to traditional NSAIDs or COX-2 inhibitor drugs.

An earlier placebo-controlled Phase 2a efficacy study in hip and knee in 248 OA patients in Europe showed that a 1.2 mg daily dose provided a highly significant efficacy profile vs. the three major OA symptoms of pain, stiffness, and physical disability.  Although this was not an active-comparator trial, the efficacy profile of CG100649 appeared to be at least as favorable as other COX-2 drugs. This prompted CrystalGenomics to conduct a supra-threshold Phase 1 Multiple Ascending Dose (MAD) study in healthy subjects last year that showed that higher doses of CG100649 (2, 4, or 8 mg per day) are likely to provide even higher levels of efficacy while maintaining CG100649's favorable safety profile.

The current Phase 2b study is a double-blind, randomized, multicenter, non-inferiority, repeat dose study of CG100649 versus celecoxib (Celebrex®) in OA patients. This is the first time that the OA efficacy of CG100649 is being tested directly against celecoxib in the same clin
'/>"/>

SOURCE CrystalGenomics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Metabolex Initiates Phase 2 Trial of Arhalofenate
2. Isis Initiates Phase 1 Study of ISIS-TTRRx and Earns $5 Million Milestone Payment From GlaxoSmithKline
3. TissueGene Initiates Patient Enrollment for a Phase II Study of TG-C for Osteoarthritis of the Knee
4. Proteon Therapeutics Initiates Patient Enrollment in Phase 2 Clinical Study of PRT-201 in Hemodialysis Patients
5. S*BIO Initiates Phase 2 Clinical Trial of its Novel JAK2 Inhibitor SB1518 in North America for Advanced Lymphoid Malignancies
6. Stephens Initiates Coverage on Vermillion
7. Cell Therapeutics Initiates Pixantrone PIX-R Pivotal Trial for Treatment of Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
8. American Regent Initiates Voluntary Nationwide Recall of Dexamethasone Sodium Phosphate Injection, USP, 4 mg/mL, 1 mL Single Dose Vials; 5 mL and 30 mL Multiple Dose Vials
9. CalciMedica Initiates Phase I Clinical Trial of First CRAC Channel Inhibitor (CCI) for Psoriasis
10. Max Neeman International Initiates Advisory Committee to Advance and Improve the Conduct of Complex Neurological Trials in India
11. Aperion Biologics Initiates Clinical Trial of Z-Lig™ Device for Anterior Cruciate Ligament Reconstruction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... 22, 2014 The Board of Directors of BD ... declared a quarterly dividend of 54.5 cents per common share ... September 9, 2014. The indicated annual dividend rate is $2.18 ... is a leading medical technology company that partners with customers ... and evolving health needs. Our innovative solutions are focused on ...
(Date:7/22/2014)... within a phylum so full of mean little creatures, the ... its cruelty -- at least to crickets. Native to the ... most predatory sort of parasite. It swoops onto the back ... and leaves its wicked brood to invade, kill and consume ... would be possible without the fly,s ability to find a ...
(Date:7/22/2014)... Institute of Standards and Technology (NIST) and California ... design for an atomic clock that is based ... , The microcomb clock, featured on the cover ... Optica ,* is the first demonstration of ... conversion of optical frequencies to lower microwave frequencies. ...
(Date:7/22/2014)... in water with ultrasound and they,ll spin around their ... yet knows exactly. But researchers at the National Institute ... it,s fast. At up to 150,000 revolutions per minute, ... object submerged in liquid ever reported. , The discovery ... that they could be used not only for moving ...
Breaking Biology Technology:Fly-inspired sound detector 2Fly-inspired sound detector 3Fly-inspired sound detector 4'Comb on a chip' powers new NIST/Caltech atomic clock design 2NIST shows ultrasonically propelled nanorods spin dizzyingly fast 2
... the Albert Einstein College of Medicine of Yeshiva University ... can cure hemophilia A (the most common form of ... online February 14 in the Journal of Clinical Investigation. ... is characterized by recurrent, spontaneous bleeding that can cause ...
... at the University of Illinois helped lead a ... strategy for serious Staphylococcus aureus (Staph) infections. The ... version of Science magazine, comes at a time ... for methicillin-resistant S. aureus) are spreading in epidemic ...
... Hospital(R), the premier pediatric research and treatment center, can ... ... More than 60,000 callers,generated $6.1 million dollars during the ... a division of Univision,Communications Inc. The radiothon, benefiting St. Jude ...
Cached Biology Technology:Transplanted cells may hold the key to curing hemophilia A, Einstein scientists report 2New approach may render disease-causing staph harmless 2New approach may render disease-causing staph harmless 3More than $6 Million Raised During Two-Day Event to Support Research and Treatment for Childhood Cancer and Other Catastrophic Diseases 2More than $6 Million Raised During Two-Day Event to Support Research and Treatment for Childhood Cancer and Other Catastrophic Diseases 3
(Date:7/22/2014)... exhibit consists of both still images and video ... scientific research. Forty-four still images were chosen from ... postdocs, staff, and alumni representing more than 25 ... more than 50 submissions. , Zach Donnell, a ... the 2014 organizers, noted that the exhibit highlights ...
(Date:7/22/2014)... Aware, Inc. (NASDAQ: AWRE ), a ... results for its second quarter ended June 30, 2014. ... million, an increase of 53% compared to $4.4 million in ... income in the second quarter of 2014 was $1.4 million ... The increase in revenue and operating income was driven by ...
(Date:7/22/2014)... professor with an expertise in big data and bioinformatics ... more than $600,000 to develop an interactive database of ... associate professor, will lead the project with professor Chris ... Engineering department. Scientists are compiling and studying data related ... involved in fruit fly development are commonly found in ...
Breaking Biology News(10 mins):Art of Science 2014 2Aware, Inc. Reports Second Quarter 2014 Financial Results 2Aware, Inc. Reports Second Quarter 2014 Financial Results 3Aware, Inc. Reports Second Quarter 2014 Financial Results 4Aware, Inc. Reports Second Quarter 2014 Financial Results 5Aware, Inc. Reports Second Quarter 2014 Financial Results 6Aware, Inc. Reports Second Quarter 2014 Financial Results 7UT Arlington big data team wins $600,000 NSF grant to build gene expression database 2
... will host its largest ever annual meeting next week ... diagnostic professionals plus 1,300 representatives from more than 180 ... sessions and 350 poster presentations, the AMP 2013 Annual ... all things molecular. The event, to be held November ...
... membrane-crossing pores, using Lego-like DNA building blocks, has been developed ... University of Cambridge and the University of Southampton. ... synthetic biology and the technique has potential applications in diagnostic ... current issue of the journal Angewandte Chemie . ...
... Mass. (November 4, 2013) Whitehead Institute scientists report ... known as Birt-Hogg-Dub cancer syndrome also prevents activation of ... This is an unexpected finding, as ... their unchecked growth and expansion. In the case of ...
Cached Biology News:The Association for Molecular Pathology announces highlights of Phoenix meeting 2Designer piercings: New membrane pores with DNA nanotechnology 2Designer piercings: New membrane pores with DNA nanotechnology 3Gene responsible for hereditary cancer syndrome found to disrupt critical growth-regulating pathway 2
Denhardt's Solution is a mixture of blocking agents used in membrane-based hybridization protocols. The solution contains 1% Ficoll (type 400) 1% polyvinylpyrrolidone and 1% bovine serum albumin. Ste...
... 97 Cytological Labeling Kit provides a unique ... of cellular targets, including cell-surface receptors and ... Kit contains the patented ELF 97 phosphatase ... precipitate at the site of enzymatic activity ...
... H 10 O 2 S 2 ... Form: White crystalline powder Assay: greater ... By IR Melting Point: greater than ... less than or equal to 1% ...
... consists of an anodized aluminum body in ... Compounds embedded in polymerized matrix. It is ... and Synergy Multi-Detection Readers. This multi-functional test ... reducing the need for tedious wet testing. ...
Biology Products: